New Treatment for COVID-19 Using Ethanol Vapor Inhalation .

Sponsor
Mansoura University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04554433
Collaborator
(none)
80
2
18

Study Details

Study Description

Brief Summary

Since ARDS is a major complication of COVID - 19 with subsequent formation of non-cardiogenic pulmonary edema , worsening the oxygenation of the patients and foamy and even bloody sputum formation, so the idea is to use alcohol inhalation as it reduce surface tension on the alveoli and markedly decrease sputum formation with improvement on oxygenation beside its cytolethal effect on virus lipid bilayer.

A lot of researches and publications proved the role of alcohol inhalation in treatment of pulmonary edema. Alcohol inhalation may has inflammatory effect and dangerous effect on patients but this can be controlled by the actual concentration used and the way we use it according to general condition of the patient and with the help of anti - inflammatory action of Asprin .

Condition or Disease Intervention/Treatment Phase
  • Drug: Ethanol with Asprin
Phase 3

Detailed Description

Corona viruses can cause diseases in both animals and humans. Many of them typically infect upper respiratory tract with minor symptoms. However, three corona viruses can infect lower respiratory tract and cause fatal pneumonia; which are severe acute respiratory syndrome corona virus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and ( SARS-CoV-2). SARS-CoV-2 shares 78% similarity of genetic material with SARS-CoV.

Pathophysiology of both viruses are closely similar, with destructive inflammatory response resulting in airway damage. That's why, disease severity in patients depends, not only on the viral infection, but also on the host response.

In many cases, this will resolve the infection. However, in other cases, immune response dysfunctions and causes severe lung and systemic pathology ending to ARDS and respiratory failure .

Treatment according to this protocol will be focused on using Asprin to decrease inflammatory reaction weather from the virus or after using alcohol.

Alcohol will be used by different methods and concentration in order to decrease surface tension on alveoli , decreasing foamy sputum secretion , increasing vascular permeability and improving oxygenation .

Also the investigator will use it as a prophylaxis for health care workers to disinfect the virus as soon as possible while it is present in nasal mucosa and upper airway.

Patients will be classified according to inclusion and exclusion criteria and will be divided into groups and they will receive the protocol as it is designed in concentrations and techniques suitable for their medical condition .

In this trial , The investigator will use 4 method to administrate Ethyl Alcohol to the patient by different concentrations .

  1. Inhaling alcohol vapor through nostrils .

  2. Inhalation of Alcohol vapor driven by Oxygen .

  3. Inhalation of Alcohol vapor driven by oxygen in case of ARDS.

  4. Ethyl Alcohol infusion into the airway . In each method , the patient will be prepared for one day before starting the protocol by prophylactic antibiotic , anti - inflammatory , mucolytic and bronchodilators .

Investigations will be made before starting for follow up of the results .

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
(A) group: will receive the new protocol . (B) group: Will receive the standard protocol .(A) group: will receive the new protocol . (B) group: Will receive the standard protocol .
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Disinfection of SARS-COV-2 ( COVID-19 ) in Human Respiratory Tract by Controlled Ethanol Vapor Inhalation Combined With Oral Asprin .
Anticipated Study Start Date :
Dec 1, 2020
Anticipated Primary Completion Date :
Oct 1, 2021
Anticipated Study Completion Date :
Jun 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Intervention

A ) Treatment group will receive a combination of Asprin in anti - inflammatory dose and controlled ethanol vapor inhalation in concentraions and technique according to their medical condition .

Drug: Ethanol with Asprin
Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms . Inhaling alcohol vapor through nostrils . Inhalation of Alcohol vapor driven by Oxygen . Inhalation of Alcohol vapor driven by oxygen in case of ARDS. Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day . Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results .
Other Names:
  • Controlled ethanol vapor inhalation combined with oral Asprin .
  • No Intervention: Control

    B ) Control group : will receive the standard protocol . Data collection will include : sociodemographic data , clinical history , results of follow up ( daily or according to clinical situation ) Follow up : to record any side effects of drugs , and swab will be taken for PCR .

    Outcome Measures

    Primary Outcome Measures

    1. Disinfection of COVID-19 in human respiratory tract . [Negative PCR test within 7 days from starting the protocol .]

      Destruction of COVID-19 in human respiratory tract and treatment of the patients with COVID 19 and Negative PCR test .

    Secondary Outcome Measures

    1. Improvement of general condition of mechanically ventilated patients confirmed COVID-19 positive .. [Negative PCR test within 10 days from starting the protocol .]

      Decrease mortality rate of mechanically ventilated patients with COVID-19 . Protection of health care workers . Negative PCR test .

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age from 20 - 60

    • Confirmed COVID-19 positive with PCR test .

    • Admitted to Mansoura university quarantine hospital ..

    • Fever ≥ 38

    • Respiratory rate ≥ 20

    • Myalgia , Arthralgia and Sore throat .

    • Radiological findings consisting with COVID-19 .

    • Welling to participate and able to give fully informed consent. Specific inclusion criteria according to the concentration and method :-

    • Inhalation of Alcohol vapor driven by Oxygen Respiratory distress ( Dyspnea - Orthopnea ) Spo2 : 65 - 85 ABG : Respiratory Alkalosis due to dyspnea and tachypnea PaO2 / FIO2 ratio > 300 mmHg under the condition in the hospital room (Moderate illness).

    • Inhalation of Alcohol vapor driven by oxygen in case of ARDS. Respiratory failure . CT : lobar collapse and nodules Non cardiogenic pulmonary edema excluded by ECHO or signs of overload . PaO2 / FIO2 ratio 101 - 300 mmHg on CPAP or Vent . ( Mild to moderate ARDS)

    • Ethyl Alcohol infusion into the airway PaO2 / FIO2 ratio ≤ 100 mmHg ( Sever ARDS )

    Exclusion Criteria:
    • Absence of any item from inclusion criteria

    • Pregnancy .

    • Signs of dehydration , Sepsis or shortness of breathing.

    • Asthmatic patients .

    • COPD .

    • Smokers ≥ 10 years .

    • Hypersensitivity to Alcohol

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Mansoura University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ragab, Resident of anesthesia and surgical ICU, Mansoura University
    ClinicalTrials.gov Identifier:
    NCT04554433
    Other Study ID Numbers:
    • 20.08.79
    First Posted:
    Sep 18, 2020
    Last Update Posted:
    Oct 28, 2020
    Last Verified:
    Oct 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ragab, Resident of anesthesia and surgical ICU, Mansoura University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 28, 2020